GH Research Reports Full Year 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
GH Research PLC (Nasdaq: GHRS) reported its full-year 2024 financial results and provided business updates. The company is progressing with its Phase 2b trial of GH001 for treatment-resistant depression, aiming for completion in Q1 2025. A Phase 1 trial for an aerosol delivery device is ongoing, and a response to an IND hold is expected by mid-2025. GHRS has $182.6 million in cash and received $139.8 million from a public offering in February 2025.
February 27, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GH Research PLC reported its 2024 financials with $182.6M in cash and $139.8M from a public offering. The Phase 2b trial for GH001 in treatment-resistant depression is on track for Q1 2025 completion, and a Phase 1 trial for an aerosol device is ongoing.
The financial results and business updates indicate a strong cash position and progress in clinical trials, which are positive indicators for GHRS. The completion of the Phase 2b trial and ongoing Phase 1 trial suggest potential advancements in their product pipeline, likely boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100